Skip to content

ULTRASOUND GUIDED TRANSFEMORAL COMPLEX LARGE-BORE PCI TRIAL

ULTRASOUND GUIDED TRANSFEMORAL COMPLEX LARGE-BORE PCI TRIAL - ULTRACOLOR Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51199
Enrollment
380
Registered
2021-05-03
Start date
2021-06-09
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis complex coronary lesion

Interventions

Ultrasound guided femoral access versus fluoroscopy guided femoral access.

Sponsors

Maatschap Cardiologie Isala Zwolle
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Use of the femoral artery for primary or secondary access with >= 7 Fr guiding catheter as indication for complex PCI, according to the expertise of the treating physician. 2) Age 18 years or older.

Exclusion criteria

Exclusion criteria: 1) Inability to obtain informed consent 2) Contra-indication for femoral access 3) Cardiogenic shock 4) ST elevation myocardial infarction

Design outcomes

Primary

MeasureTime frame
To investigate if ultrasound guided primary femoral access is associated with less clinically relevant access site related bleeding (BARC 2,3 or 5) and/or vascular complication requiring intervention as compared to fluoroscopy guided cannulation for complex PCI with large-bore access.

Secondary

MeasureTime frame
To compare ultrasound guided with fluoroscopy guided femoral access for complex PCI with large-bore access with regard to the following objectives (definitions in appendix I): - BARC 2, 3 or 5 access-site related bleeding or vascular complication of secondary access site (femoral or radial, defined in appendix I) - MACE - Procedural duration - First pass puncture - Accidental venous puncture - Vascular complication not requiring intervention - Vascular closure device failure

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)